GSK licenses breast cancer drug rights to Chinese firm

04/10/2013 | Pharmaceutical Business Review Online

GlaxoSmithKline China granted Eddingpharm exclusive rights to import, promote, market and distribute breast cancer drug Tykerb, or lapatinib, in mainland China. With capecitabine, Tykerb is used for patients with HER2-positive metastatic breast cancer who previously received anthracycline, a taxane and trastuzumab.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC